This inventor holds 3 USPTO granted patents and 3 published patent applications and 3 EPO patents. Top assignees: The Asan Foundation, Cmg Pharmaceutical Co., Ltd., University of Ulsan Foundation for Industry Cooperation. Active years: 2017-2020.
Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile
Company Filing History:
2 out of 84 
1 out of 6 
1 out of 94 
Years Active: 2017-2020
Title: Jung Shin Lee: Innovator in Cancer Treatment
Introduction
Jung Shin Lee is a prominent inventor based in Seoul, South Korea. He has made significant contributions to the field of cancer treatment through his innovative research and patented inventions. With a total of 3 patents, Lee's work focuses on enhancing the effectiveness of cancer therapies.
Latest Patents
One of his latest patents is a method for determining sensitivity to a simultaneous inhibitor against poly ADP ribose polymerase (PARP) and Tankyrase. This invention aims to maximize colorectal treatment effects by identifying patients who are sensitive to this combined inhibitor. Another notable patent is a composition for the treatment or metastasis suppression of cancers, which includes a p34 expression inhibitor or activity inhibitor as an active ingredient. This invention highlights the potential of p34 gene expression inhibitors in reducing the clonogenic and tumor-forming potential of various cancer cells.
Career Highlights
Jung Shin Lee has worked with reputable organizations, including the Asan Foundation and the University of Ulsan Foundation for Industry Cooperation. His career reflects a commitment to advancing cancer research and treatment methodologies.
Collaborations
Lee has collaborated with notable colleagues such as Dong Hoon Jin and Seung Woo Hong, contributing to the collective effort in cancer research and innovation.
Conclusion
Jung Shin Lee's contributions to cancer treatment through his patents and collaborations underscore his role as a key innovator in the field. His work continues to pave the way for advancements in cancer therapies.
Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile